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Background: Despite progress in identifying genes associated with breast cancer, many more risk loci exist.
Genome-wide association analyses in genetically-homogeneous populations, such as that of Sardinia (Italy), could
represent an additional approach to detect low penetrance alleles.
Methods: We performed a genome-wide association study comparing 1431 Sardinian patients with non-familial,
BRCA1/2-mutation-negative breast cancer to 2171 healthy Sardinian blood donors. DNA was genotyped using GeneChip
Human Mapping 500 K Arrays or Genome-Wide Human SNP Arrays 6.0. To increase genomic coverage, genotypes of
additional SNPs were imputed using data from HapMap Phase II. After quality control filtering of genotype data, 1367
cases (9 men) and 1658 controls (1156 men) were analyzed on a total of 2,067,645 SNPs.
Results: Overall, 33 genomic regions (67 candidate SNPs) were associated with breast cancer risk at the p < 10−6 level.
Twenty of these regions contained defined genes, including one already associated with breast cancer risk: TOX3. With
a lower threshold for preliminary significance to p < 10−5, we identified 11 additional SNPs in FGFR2, a well-established
breast cancer-associated gene. Ten candidate SNPs were selected, excluding those already associated with breast cancer,
for technical validation as well as replication in 1668 samples from the same population. Only SNP rs345299, located in
intron 1 of VAV3, remained suggestively associated (p-value, 1.16x10−5), but it did not associate with breast cancer risk
in pooled data from two large, mixed-population cohorts.
Conclusions: This study indicated the role of TOX3 and FGFR2 as breast cancer susceptibility genes in BRCA1/2-wild-type
breast cancer patients from Sardinian population.
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Breast cancer is the most common malignancy in women
in western countries, currently accounting for one-third of
all female cancer cases [1]. A family history of breast can-
cer is the principal risk factor for developing the disease
[2]. Linkage studies in families have identified several
high-penetrance mutations in BRCA1, BRCA2 and other
genes as causative of disease in 5 %-10 % of cases [3, 4].
Additionally, a combined approach of family-based and
case–control studies revealed that mutations in several
genes encoding proteins involved in DNA repair and func-
tionally interacting with the BRCA1/2 proteins are associ-
ated with a moderate risk of breast cancer, contributing to
another 10 %–15 % of cases [5]. Genome-wide association
(GWA) studies have so far identified at least 72 common
lower penetrance alleles associated with breast cancer [6,
7]. A large fraction of these susceptibility alleles are associ-
ated with increased risk in persons with a family history of
breast cancer despite the absence of mutations in BRCA1
or BRCA2, accounting for about 30 % of the familial risk
of the disease [7]. Other alleles, such as those that map to
the FGFR2 and TOX3 genes, act as risk modifiers in
BRCA1/2-mutation carriers [3, 8, 9].
Results from a meta-analysis of GWA studies suggest
that a substantial fraction of the residual familial ag-
gregation cases can be explained by other common
single nucleotide polymorphisms (SNPs) not yet iden-
tified [7]. In particular, the authors hypothesized that
more than 1000 additional loci may be involved in
breast cancer susceptibility. Because of their low pene-
trance and the small fraction of familial cases, it is un-
likely that other susceptibility genes will be identified
through additional family-based studies. A promising
approach could be to conduct new studies in non-
familial cases, such as case–control in populations
with less genetic heterogeneity.
One population with notable genetic inter-relatedness
is that of the Mediterranean island of Sardinia (Italy).
In Sardinia, breast cancer represents the principal
death-causing malignancy among women, with an in-
cidence similar to that observed in other western
populations [10]. The Sardinian population (1.67 million
in 2010, according to the Italian National Institute of
Statistics) is isolated, with considerable inter-relatedness
and founder effects for several genetic diseases (e.g.
thalassemia) [11, 12]. The relatively homogeneous gen-
etic make-up of the Sardinian population offered an op-
portunity to search for genetic determinants of breast
cancer, requiring fewer cases to establish association
with a susceptibility locus than do mixed populations.
We have conducted such a case–control GWA study
for breast cancer risk in our collection of Sardinian
breast cancer patients who are negative for BRCA1 or
BRCA2 mutations.Methods
Breast cancer cases and controls
From January 1998 to December 2006, we recruited
1698 patients with breast cancer from the four main
oncology units in the Region of Sardinia (Azienda
Ospedaliero Universitaria of Sassari, Azienda Sanitaria
Locale of Sassari, Businco Oncologic Institute, and
University of Cagliari). This cohort includes 1085
patients recruited in 1998-2003 [13]. Inclusion criteria
were: (i) a histopathological diagnosis of any type of
breast cancer, and (ii) self-reported Sardinian origin,
defined as both biological parents and all four bio-
logical grandparents born on the island. No exclusion
criteria were applied; in particular, patients were not
selected for age, gender, grade or stage of cancer, or
family history of any cancer.
Family history for cancer was evaluated through
specific questionnaires during the follow-up visits at
the different departments of the participating institu-
tions. Cases were classified as non-familial when less
than three (0, 1, or 2) affected members with breast or
ovarian cancer were present in first- and second-degree
relatives. A sample of peripheral blood was obtained for
DNA extraction. Pathological TNM (tumor, node,
metastasis) classification and immuno-histochemistry
profile for estrogen receptors (ER), progesterone
receptors (PR) and HER2 (receptor tyrosine-protein
kinase erbB-2) were also obtained, when available.
Controls consisted of 2171 healthy persons recruited
at community blood donation centers across the island
and at the transfusion center of Azienda Ospedaliera
Brotzu in Cagliari. Controls were included if at least
three out of four grandparents were born in Sardinia
and if they reported no type of cancer for their
first-degree relatives. Overall, 1503 (69.2 %) were
males, in line with the male preponderance among
Italian blood donors [CENSIS at http://www.censis.it/]
(Fig. 1). Since the present study was aimed at detecting
low penetrance alleles at autosomic level, no significant
differences were expected by the use of control males.
In fact, allelic transmission is identical in males and
females as the entire population should comply with
the Hardy Weinberg law. As some randomness is
expected, we specifically assessed our best SNPs for the
impact of males in the controls set, excluding bias. This
was added to a genome-wide check of allele frequency
distribution between genders. Of note, the same approach
of including males among controls has also been adopted
by previous studies [14–16], all of them reporting a
genome-wide check of differences between males and
females, with no significant diversity in alleles’ distribu-
tion. In such latter studies, percentages of male controls
were reported to up to 78 %, which is thus consistent with
the frequency (69 %) reported in our series.
Fig. 1 Flow chart of the selection of cases and controls throughout the study
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for their biological samples and clinical data to be used
for research purposes. The study protocol was reviewed
and approved by the Ethics Committee of the ASL8
Cagliari and the Bioethics Committee of the Sassari
Healthcare District.
BRCA mutation analysis
From our cohort of 1698 breast cancer patients, we se-
lected 1452 non-familial cases who were then tested for
BRCA1 and BRCA2 germline mutations. The entire cod-
ing sequences and intron-exon boundaries of the BRCA1
and BRCA2 genes were screened by denaturing high-
performance liquid chromatography (DHPLC) followed
by direct sequencing on an automated DNA sequencer
(ABI Prism 3100 Genetic Analyzer, Applied Biosystems,
Foster City, USA). Protocols for PCR-based amplification
and mutation analysis of exons and exon-intron boundar-
ies were as previously reported [17]. Familial cases (N =
246) were excluded on the basis of the presence of at least
three family members (the proband and at least two other
first- or second-degree relatives) having with either breast
or ovarian cancer. Overall, 21 cases (1.4 %) had a mutation
in BRCA1 or BRCA2 and were excluded, leaving 1431
cases for the GWA study. The median age of the 1431
cases at diagnosis was 60 (range, 23–98); 11 cases (0.8 %)
were male (Fig. 1).
Genotyping and quality controls
DNA was isolated from peripheral blood and stored
at -80 °C. Genotyping was performed at the Institute of
Genetic and Biomedical Research using Affymetrix
technology according to the manufacturer’s protocols.
At first, 740 cases and 412 controls were genotypedusing the GeneChip Human Mapping 500 K Array Set
(analyzed from 2005 to 2006). The rest, 691 cases and
1759 controls, were assayed in the same center with the
newer Genome-Wide Human SNP Array 6.0 (analyzed
from 2007 to 2009) (Fig. 1).
Genotypes for individuals assessed with the 500 K
Array and the 6.0 array set were called respectively with
the BRLMM algorithm and with Birdseed v2 [18]. The
latter algorithm was applied to a unique cluster contain-
ing all cases and controls, given its sensitivity to plate
bias. A methodological limitation of the current study
came from the use of two different microarray genotyp-
ing platforms. This choice was due to the adoption of
the larger Array 6.0 (permitting the testing of 900 K
SNPs) when it became available, but it was not feasible
to retest the initial 740 cases and 412 controls with the
larger panel. As a result, we analyzed directly only those
SNPs that were represented on both platforms (240742
SNPs). Individuals with a SNP call rate <90 % were
excluded from the analysis, as were individuals whose
recorded gender was different from that predicted by the
genetic data.
SNPs showing significant (p < 1x10−6) deviation from
Hardy-Weinberg equilibrium in controls, minor allele
frequency (MAF) <5 % or sample call rate <95 %, were
filtered out. Moreover, for SNPs tested on both plat-
forms, those with allele frequencies differing by >10 % in
controls were excluded. We then left out all SNPs that
were not represented on both platforms. Finally, to en-
sure that the dataset contained only unrelated persons,
we used RELPAIR software [19] to estimate genotype
sharing between all possible pairs of individuals based
on a subset of 10000 quality-checked SNPs. When two
persons were found to be first-degree relatives, we
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pair consisted of one case and one control, in which we
excluded the control.
To avoid bias introduced by population stratification,
we performed principal component analysis (PCA) using
Eigensoft 3.0 software [20, 21]. Individuals flagged as
outliers in the PCA analyses (>6 standard deviations
from the mean) were excluded. The principal component
eigenvectors for the remaining individuals were recalcu-
lated and the axes were then used as covariates to calculate
adjusted p values for association with breast cancer; the
genomic control parameter was 1.149 (Additional file 1:
Figure S1). For all SNPs with adjusted p < 10−6, we visually
inspected the discrimination plots and kept only those with
good plots (three distinct data clusters). A PCA sup-
porting the overall homogeneity of our Sardinian sam-
ple in respect to general Europeans is showed in
Additional file 2: Figure S2.
Imputation and identification of candidate SNPs
To improve coverage of the genome, we increased the
set of SNPs tested for association through imputation.
MACH software (version 1.0) was used to impute non-
genotyped markers based on the phased haplotypes from
HapMap Phase II (CEU, release 22) and the set of
270742 quality-controlled markers represented on both
platforms. Imputation increased the SNP coverage to a
total of 2067645 markers (Additional file 3: Table S1),
though without direct scoring of SNPs that might have
had higher p-values.
After imputation, we considered only markers with
MAF > 1 % and imputation quality (RSQR) >0.3 (RSQR
infers r2 between true and estimated allele counts [22]).
These markers were assessed with a likelihood ratio test
to identify those with additive effects on modifying the
risk of breast cancer; this test was implemented in
mach2dat, in the MACH package, using allele dosages
and the estimated eigenvectors as covariates in the
model. We selected SNPs with p < 1x10−6 and examined
the discrimination plots of all the other genotyped SNPs
in the surrounding 200 kb genomic region. SNPs resid-
ing in genomic regions where all other genotyped SNPs
had good discrimination plots were considered candidate
markers.
Validation of candidate markers
Validation of the SNPs classified as candidate markers,
was done by regenotyping them with custom TaqMan
SNP genotyping assays (Life Technologies). This valid-
ation step was done using DNA from a subset of the
Sardinian cases (1362) and controls (1514) in this study
who passed quality control filtering at the sample level
in microarray genotyping (SNP call rate >90 % and no
error in gender determination).We attempted to replicate promising signals in a wider
set of DNAs consisting in additional 201 Sardinian cases
and 1467 controls (630 females and 1038 males) col-
lected after December 2006 within the same study
protocol and with the same features as the original set.
Replication analyses were performed using data from a
combined analyses of eleven GWAS in other popula-
tions of European ancestry, comprising 16,195 cases and
18,980 controls, and data from 45,290 cases and 41,880
controls of European ancestry from 41 studies collabor-
ating in the Breast Cancer Association Consortium
(BCAC), which were genotyped with a custom array
(iCOGS) ([7]; http://gameon.dfci.harvard.edu/gameon).
For all studies except BCFR, BPC3 and TNBCC, geno-
types were estimated by imputation, using IMPUTE2 [23]
and the 1000 genomes March 2012 release as a reference
panel, after prephasing with SHAPEIT [24]. Per-allele odds
ratios (ORs) and standard errors for individual studies were
generated using SNPTEST [25]. BCFR, BPC3 and TNBCC
performed imputation using MACH and Minimac. Esti-
mated ORs for the combined analysis were generated using
a fixed-effect meta-analysis, using METAL [22]. For the
combined analysis of the GWAS and iCOGS, we reana-
lyzed the iCOGS data to remove samples also included in a
GWAS, to generate independent datasets.
Genotype associations with clinical data
Chi-square and Fisher’s exact tests were used to evaluate
possible associations between tumor phenotype (ER, PR,
HER2, pT, pN, M) and the genotypes of candidate SNPs.
Statistical tests were performed using SPSS statistical
software, version 15.0. All tests were two-tailed and a
p < 0.05 indicated significance.
Evaluation of GWAS-identified breast cancer risk variants
in our Sardinian cohort
GWA studies have so far identified at least 72 common
lower penetrance alleles associated with a mild increase in
the risk of breast cancer [6, 7]. We evaluated index SNPs
(when not available, proxies) in all 72 breast cancer sus-
ceptibility loci identified to date in our subset cohort
(1367 cases and 1658 controls).
Results
To search for new loci associated with breast cancer
risk, we genotyped germline DNA of 1431 Sardinian pa-
tients with sporadic breast cancer (BRCA-mutation-
negative) and a set of 2171 healthy blood donor controls.
After quality control filtering of genotype data at the
sample level, 1367 cases and 1658 controls were ana-
lyzed. For 921 cases (67 %), we had data regarding TNM
classification and receptor status (Table 1). Among the
775 patients tested for all three receptors, the predomin-
ant molecular subtype was ER+/PR+/HER2-, found in
Table 1 Tumor characteristics at the time of diagnosis, for 921
patients (all women) with sporadic, BRCA-mutation-negative
breast cancer
Characteristic Patients, n (%)
Pathological TNM classification
pT1-2 830 (90.1)
pT3-4 91 (9.9)
pN0 533 (57.9)
pN1 388 (42.1)
M0 751 (81.5)
M1 43 (4.7)
Mx 127 (13.8)
Receptor status
ER- 234 (25.4)
ER+ 687 (74.6)
PR- 260 (28.2)
PR+ 661 (71.8)
HER2- 601 (65.3)
HER2+ 174 (18.9)
Not tested 146 (15.8)
Molecular subtypea
ER+/PR+/HER2- 545 (70.3)
ER+/PR+/HER2+ 142 (18.3)
ER-/PR-/HER2+ 32 (4.1)
Triple negative (ER-/PR-/HER2-) 56 (7.2)
ER, estrogen receptor; PR, progesterone receptor.
a For the 775 cases tested for all three receptor markers.
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negative (ER-/PR-/HER2-) cases was low, 7.2 %.
The genome wide analysis conducted on a set of
2067645 markers (Methods and Additional file 4: Table
S6), revealed 33 genomic regions on 20 chromosomes that
were suggestively associated with breast cancer risk
at p < 1x10−6 (Fig. 2). In particular, 7 regions reached the
genome wide significance threshold (p = 5x10−8; Table 2).
The 33 suggestive genomic regions contained a total of 67
SNPs with p < 10−6 (Table 2, Additional file 3: Table S2).
One of the identified regions, on chromosome
16q12.1, includes TOX3, a gene already associated with
breast cancer risk. For this gene, 19 SNPs had p < 10−6
(Additional file 3: Table S2), supporting a significant sus-
ceptibility role for TOX3 in the Sardinian as well as
other populations.
For a second gene already associated with breast
cancer, FGFR2 on chromosome 10q26.13, no SNP
had p < 10−6 but 11 were associated at a less restrict-
ive p < 10−5 (Additional file 3: Table S2).
No additional SNP with p < 1x10−5 lay near a gene
already associated with breast cancer. Finally, the
four SNPs tested in BRCA1 and those in BRCA2 allhad p > 0.05, implying no association with breast cancer in
this series. This negative result is consistent with our
study’s explicit exclusion of patients with BRCA mutations
in order to focus on other, low-penetrance loci.
We then attempted to validate the results for ten candi-
date SNPs, selected among those in genes not already
associated with breast cancer, by regenotyping them by
TaqMan Assays in a subset of the Sardinian cases and
controls (1362 cases and 1514 controls) (Table 3). These
markers included nine SNPs in a known gene in the sur-
rounding 200 kb (rs345299, rs6661074, rs13393791,
rs17032957, rs1928482, rs1903974, rs11178748, rs963950,
rs857989) and one additional SNP (rs10979327) in a desert
region but with p = 2.92x10−25. Of these SNPs, only one,
rs345299 reached an association of p = 5.38x10−5, while it
reached p = 9.40x10−7 in the original analysis (Tables 2
and 3). The difference between the two p-values could
be partially explained by the call rate, equal to 97 %
when using TaqMan. The concordance between genotypes
and dosages is consistent with the potential of the signal
as a candidate (Table 3). Furthermore, extending the valid-
ation to an additional 201 cases and 1467 controls (leading
to a total set of 1563 BC cases/2981controls for analyses)
the p-value reached p = 1.16x10−5, increasing the robust-
ness of the signal. SNP rs345299 resides in intron 1 of
VAV3, an oncogene that encodes a guanine nucleotide ex-
change factor. Both microarray and TaqMan assays sug-
gested that the C allele at this position is associated with
disease risk.
To assess further the significance of this result, we
tried to replicate the association of rs345299 with breast
cancer risk in a combined analysis of eleven GWAS,
comprising 16,195 cases and 18,980 controls, together
with data from a custom array (iCOGS) genotyped on
45,290 cases and 41,880 controls of European origin.
rs345299 was present on only one of the GWAS arrays
but was well imputed in the other GWAS (r2 = 0.94 to
0.99) and on the iCOGS array with r2 = 0.63. No evi-
dence of association was found in either analyses, nor
was there any evidence of association in the iCOGS
when analyses were restricted to ER-positive or ER-
negative disease (Additional file 3: Table S3). Unfortu-
nately, replication failed suggesting that further analyses
are necessary to distinguish whether it is a false positive
or an effect specific for the Sardinian population. Test-
ing this hypothesis requires a larger set of patients.
Finally, in a post-hoc analysis, we took advantage of
the availability of TNM classification and receptor status
data for 921 cases (Table 1) to look for associations be-
tween six cancer phenotypes and the cases’ genotypes at
34 candidate SNPs (those in Table 2 plus rs11200014 for
FGFR2). In all cases, the statistical tests of association
gave p > 0.05, suggesting that the candidate markers for
breast cancer risk are not associated with clinical or
Fig. 2 Manhattan plot for this genome-wide association study of sporadic breast cancer in Sardinian population. Data shown are the negative
logarithm of the association p-value for each single nucleotide polymorphism. The horizontal line indicates the significance cut-off at p < 10−6
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the 72 breast cancer susceptibility variants identified so
far in population meta-analysis in our Sardinian cohort.
We were able to detect only rs2981579 (FGFR2) and
rs3803662 (TOX3) with p-values of 3.5x10−6 and 5.18x10−6,
respectively (Additional file 3: Table S4). However, if the ef-
fect sizes in Sardinian are similar to those reported in other
Europeans our sample size is likely underpowered to find
associations in the other known genes.
Discussion
In our Sardinian cohort of breast cancer patients, the pre-
dominant molecular subtype was ER+/PR+/HER2- and
the percentage of triple-negative cases (7.2 % among those
tested) was low. Rates of triple-negative breast cancer have
been variably reported in the range of 10 %–20 % in differ-
ent studies [26]. The somewhat lower rate reported here is
in line with findings from two other recent Italian studies:
8.7 % among 2347 patients in Modena [27] and 4.8 %
among 2112 patients in Trentino [28].
Our study includes males in the control population,
who were recruited for parallel projects. While we havedemonstrated that their inclusion in the GWAS does
not introduce a bias, we acknowledge this as one of the
limitations of the study, along with the low number of
cases and controls compared to other reported GWAS
in Europeans. Nevertheless, we proceeded with GWAS
considering that, in addition to its inter-relatedness, the
Sardinian population is relatively stable in towns, with a
largely shared lifestyle and diet across the island; thus,
both epidemiological and genetic factors are less hetero-
geneous than in cosmopolitan European populations,
with an expected increase in the power to detect associ-
ations. Furthermore, GWAS has been successfully done
in this population to identify disease-associated alleles
in another instance with a limited number of cases/
controls [29]. Finally, with our sample size we are com-
pletely underpowered to detect low penetrance alleles
(OR ~1.05) as those recently described by others. We
are instead powered to find alleles with moderate effect
size (>1.3) that are poorly tagged in other populations
by HapMap SNPs but well captured in Sardinians.
We used SNP genotyping microarrays and identified 33
genomic regions (67 SNPs) associated (at the p < 10−6
Table 2 Most significant SNPs in 33 genomic regions associating at the p < 10−6 level with sporadic, BRCA-mutation-negative breast
cancer cases in the Sardinian population
Chromosomal
region
SNP Position Alleles Frequency RSQR OR (CI 95%) p Gene
Cases Controls
1p35.1 rs9425977 34238042 C/T 0.082 0.059 0.379 2.597 (1.817 - 3.709) 9.51E-08 CSMD2
1p34.1 rs2477618 44271050 C/G 0.077 0.058 0.416 2.312 (1.647 -3.245) 9.13E-07 -
1p13.3 rs345299 108249656 A/C 0.465 0.534 0.957 0.755 (0.676 - 0.845) 9.40E-07 VAV3
1q32.1 rs6661074 203605742 A/G 0.483 0.425 0.731 1.408 (1.235 - 1.605) 3.10E-07 LEMD1
2p25.3 rs13393791 3239073 C/T 0.074 0.039 0.989 1.862 (1.469 - 2.361) 1.99E-07 TSSC1
2p21 rs17032957 45134208 A/G 0.701 0.747 0.462 0.597 (0.500 - 0.712) 9.17E-09 SIX2/SIX3
2q37.1 rs838436 232291757 A/G 0.908 0.926 0.308 0.415 (0.291 - 0.592) 8.45E-07 -
3p14.1 rs9810816 67158548 C/G 0.935 0.955 0.404 0.368 (0.251 - 0.541) 1.86E-07 -
5q35.2 rs17076993 173564400 C/T 0.071 0.049 0.447 2.507 (1.768 - 3.553) 1.29E-07 -
6q23.1 rs3777428 130495535 C/T 0.926 0.952 0.720 0.509 (0.387 - 0.668) 8.48E-07 L3MBTL3
7p14.2 rs6968002 36531229 C/T 0.938 0.958 0.533 0.431 (0.308 - 0.603) 6.32E-07 AOAH
8q24.3 rs11785598 144537061 C/T 0.948 0.929 0.328 3.420 (2.223 - 5.266) 6.40E-09 RHPN1
9q22.32 rs10512243 97815280 A/G 0.093 0.056 0.913 1.754 (1.411 - 2.181) 2.78E-07 -
9q31.2 rs10979327 110160516 G/T 0.112 0.060 0.632 3.851 (2.955 - 5.016) 2.92E-25 -
9q33.3 rs1928482 125472269 C/T 0.361 0.303 0.978 1.362 (1.206 - 1.538) 4.87E-07 DENND1A
9q34.13 rs1633769 134869098 C/G 0.769 0.803 0.393 0.558 (0.452 - 0.690) 6.07E-08 -
9q34.3 rs3811159 136828478 A/G 0.608 0.661 0.683 0.706 (0.616 - 0.810) 6.07E-07 COL5A1
10q21.1 rs1903974 53549083 A/G 0.047 0.077 0.865 0.527 (0.409 - 0.680) 4.38E-07 PRKG1
11p12 rs7947387 38902742 A/G 0.050 0.069 0.333 0.347 (0.230 - 0.523) 2.45E-07 -
12q21.1 rs11178748 70021794 A/G 0.100 0.078 0.897 1.673 (1.366 - 2.046) 5.15E-07 TSPAN8
12q23.3 rs7488485 105789959 C/T 0.097 0.073 0.404 2.348 (1.722 - 3.198) 3.17E-08 RIC8B
13q21.1 rs9569528 56234110 C/T 0.074 0.051 0.492 2.481 (1.782 - 3.456) 5.27E-08 -
14q23.1 rs17097373 59896563 C/T 0.076 0.058 0.770 1.861 (1.448 - 2.391) 9.43E-07 -
15q12 rs17651375 25763160 C/T 0.084 0.056 0.934 1.761 (1.417 - 2.189) 2.93E-07 OCA2
16q12.1 rs2193094 51123955 G/T 0.557 0.478 0.982 1.337 (1.198 - 1.491) 1.70E-07 TOX3
16q21 rs8045513 60720397 A/T 0.059 0.088 0.606 0.430 (0.326 - 0.569) 9.49E-10 -
18p11.22 rs17436811 10080771 C/T 0.084 0.058 0.644 2.002 (1.536 - 2.608) 2.20E-07 -
19q13.31 rs17725531 49018018 G/T 0.140 0.099 0.930 1.560 (1.311 - 1.858) 5.82E-07 -
20p12.2 rs6039942 10376146 A/G 0.100 0.068 0.623 2.005 (1.565 - 2.565) 2.13E-08 C20orf94
21q22.11 rs2833424 31774071 A/G 0.293 0.239 0.985 1.365 (1.206 - 1.544) 8.42E-07 TIAM1
21q22.11 rs963950 33438577 C/T 0.930 0.883 0.986 1.742 (1.432 - 2.119) 1.24E-08 IFNAR2
21q22.13 rs857989 38042001 C/G 0.154 0.111 0.896 1.537 (1.301 - 1.816) 3.72E-07 KCNJ6
22q12.3 rs6000351 35340813 A/G 0.093 0.069 0.445 2.100 (1.556 - 2.835) 7.44E-07 CACNG2
The table reports, for each SNP, the genomic cytoband, the rs name, the position in build36, the corresponding alleles, the frequency in cases and controls, the
imputation quality, the OR and its confidence interval, the pvalue and the most candidate gene within 200 kb. Additional SNPs in the same genomic regions are
listed in Additional file 3: Table S2.
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breast cancer. Of these genomic regions, 20 contained
known genes. However, only one of these genes, TOX3,
has already been associated with breast cancer in other
population-based studies. When we lowered the criterion
for significance to p < 10−5, we also identified 11 SNPs in
FGFR2, another known breast cancer-associated gene.The attempt to validate 10 of the 67 SNPs selected
as candidate markers by singleplex genotyping for
technical validation in the original GWA and then in
additional samples one, rs345299, that reached a p-value
of 10−5 (p = 1.16x10−5). The robustness of the signal is
supported by the high concordance and by the increase in
significance when additional samples are included. This
Table 3 Association results for the 10 candidate SNPs
A
SNP corr FREQ1 cases FREQ1_CT N p-value n.a. p-value*
rs857989 0.811 0.131 0.106 2866 3.99E-03 4.02E-03
rs11178748 0.824 0.083 0.079 2848 0.289 0.560
rs1903974 0.940 0.043 0.070 2837 5.94E-06 1.34E-05
rs1928482 0.895 0.351 0.313 2771 1.09E-03 2.24E-03
rs10979327 0.697 0.078 0.069 2840 0.178 0.220
rs17032957 0.651 0.749 0.748 2816 0.879 0.910
rs13393791 0.793 0.051 0.041 2847 0.093 0.068
rs6661074 0.806 0.474 0.434 2855 3.62E-03 2.23E-03
rs345299 0.885 0.477 0.530 2789 5.38E-05 9.05E-05
rs17633986 0.809 0.890 0.882 2822 0.553 0.331
B
MARKER ALLELES FREQ1_cases FREQ1_CT N n.a. p-value*
rs857989 C/G 0.130 0.106 4469 8.02E-04
rs11178748 A/G 0.083 0.088 4432 0.499
rs1903974 A/G 0.044 0.063 4440 2.40E-04
rs1928482 C/T 0.350 0.319 4344 3.42E-03
rs10979327 G/T 0.078 0.074 4456 0.506
rs17032957 A/G 0.751 0.750 4414 0.865
rs13393791 C/T 0.050 0.045 4441 0.365
rs6661074 A/G 0.470 0.442 4416 0.010
rs345299 A/C 0.481 0.531 4343 1.16E-05
rs17633986 C/T 0.889 0.877 4451 0.100
A. Results on Taqman genotypes for 1362 breast cancer cases and 1514 controls included in the GWAS.
B. Results on Taqman genotypes for all 1563 breast cancer cases and 2981 controls.
*n.a. p-value: not adjusted p-value, not corrected for population stratification.
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ciated with breast cancer in two other mixed-population
cohorts, so that further studies are necessary to clarify
whether this marker nevertheless represents a susceptibility
locus specific to Sardinians. However, involvement of VAV3
in carcinogenesis is further supported by other recent
studies.
VAV3 is a well-characterized guanine nucleotide ex-
change factor that, upon phosphorylation by receptor
tyrosine kinases, participates in signal transduction
pathways, resulting in changes in gene expression, cell
cycle and cytoskeleton rearrangement [30]. Its activa-
tion is thought to be involved in both prostate [31, 32]
and breast [33, 34] cancer development and progres-
sion, in some cases through stimulation of androgen
and ER receptors, respectively [35, 36]. Interestingly,
the vast majority (about 75%) of breast cancer patients
in our series was positive for ER expression (see Table 1).
On the basis of such findings, further studies, such as
VAV3 gene and protein expression in breast cancer samples
from Sardinian cases in relation to the genotype, will helpin better understanding the association of the SNP with the
disease.
Overall, even when the results of analyses in different
populations are not mutually confirmatory, they can
provide valuable information of wider importance. As an
example, FGFR2 and TOX3, which were previously dem-
onstrated to act as risk modifiers in BRCA1/2 mutation
carriers [9, 37], were shown to be associated here in pa-
tients without germline mutations in BRCA1/2. In this
context, VAV3 may possibly lack a range of gene varia-
tions significant for cancer risk in other populations.
This would be consistent with the common view that
breast cancer patients from different areas may have
different genetic backgrounds that influence the im-
pact of low-penetrance susceptibility genes on disease
risk.
Conclusions
In the present study, a case–control GWA study for
breast cancer risk was carried out in a large collection of
Sardinian breast cancer patients negative for BRCA1 or
Palomba et al. BMC Cancer  (2015) 15:383 Page 9 of 10BRCA2 mutations. Among the disease-associated genomic
regions, TOX3 and FGFR2 genes have been identified as
breast cancer susceptibility genes in BRCA1/2-wild-type
breast cancer patients from Sardinia. Future functional
studies on such candidate genes will provide further de-
tails about their role in pathogenesis of breast cancer in
Sardinian population.
Availability of supporting data
Genetic results can be downloaded in bulk or searched for
SNPs or genes at the web site of the Istituto di Ricerca
Genetica e Biomedica (IRGB), National Research Council
(CNR), Cagliari, Italy (http://www.irgb.cnr.it/facs/facs.php).
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Sardinian and HapMap2-CEU samples based on principal component axis
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genome-wide SNPs. Each point represents one individual and is colored
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genotype data: only the 270742 quality-checked SNPs shared between the
two platforms were used in the analysis. Table S2. Additional SNP data from
the Sardinian breast cancer GWA study. Shown are: (i) additional SNPs
associated with breast cancer at the p<10-6 level but not shown in
Table 2, (ii) set of 11 SNPs in FGFR2 having p<10-5 and (iii) set of SNPs in
BRCA1 and BRCA2. Table S3. Replication results for the association of
rs345299 with breast cancer risk in two larger cohorts, CGEMS and BCAC.
Table S4. Evaluation of candidate SNPs within known 72 breast cancer
susceptibility loci in Sardinia cohort (1,367 cases and 1,658 controls).
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reported in Table 2.
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